June 5, 2025 8:03am

Uncle algo and his electronic trading dwarfs are “thirsting” for trade profits

The U.S. economy has contracted over the past 6-weeks as hiring has slowed and consumers and businesses worried about tariff-related price increases, according to the Fed’s “Beige Book” but, there were disparities!”

News: REGENXBIO (RGNX +$0.41 or +4.07% pre-open) new positive interim data from the P1/2 AFFINITY DUCHENNE trial. Updates include positive functional, safety and biomarker data for RGX-202, REGENXBIO's investigational gene therapy for Duchenne muscular dystrophy. The functional data demonstrate consistent benefit among dose level 2 participants at 9-and 12-months following treatment with RGX-202. "These findings suggest that the microdystrophin expression observed with RGX-202 is leading to meaningful functional improvements, even in individuals with DMD who are expected to experience functional decline," said Aravindhan Veerapandiyan, M.D., of Arkansas Children's Hospital.

Breaking: Jobless claims last week came in at 247,000, an increase of 8,000 from the week before and more than the 236,000 that economists were expecting. Continuing claims, which run a week behind, edged though the four-week moving average rise to its highest level since Nov. 27, 2021. In related news, unit labor costs, which measure compensation against productivity, unexpectedly increased 6.6% in the first quarter, according to a revised estimate from the Bureau of Labor Statistics. Productivity fell 1.5%, more than the expected decline of 0.8%.

Pre-open Indications: 4 Sell into Strength

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Wednesday’s night’s … RegMed Investors (RMi) Closing Bell: Gauging sector breadth … https://www.regmedinvestors.com/articles/13946

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

  • Questions exist as stock dives in afternoon -$0.7141 to $0.93 with 5000 shares traded and suddenly is “resurrected” at the close to +$0.01 with 9,250 shares traded – PONZI Scheme at its best or was convicted Bernie Madoff also resurrected in DST Capital (run by HRGN’s President)???

 

Thursday: The pre-open Dow futures are UP +0.21% or (+89 points), the S&P futures are UP +0.23% or (+13 points) and the Nasdaq futures are UP +0.19% or (+41 points)

  • Stock futures are positive but, barely moving i.e., little changed on Thursday,
  • European shares open slightly higher before European Central Bank later (ECB) decision,
  • Asia-Pacific markets traded mixed

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

 

The 3-major U.S. indexes are tracking for gains so far this week; the S&P 500 is up 1%, while the Dow has added 0.4% and the Nasdaq has jumped 1.8% week to date.

  • Wednesday: The Dow closed DOWN -91.90 points or -0.22%, the S&P closed UP +0.44 points or +0.01% while the Nasdaq closed UP +61.53 points or +0.32%
  • Tuesday: The Dow closed UP +214.16 points or +0.51%, the S&P closed UP +34.43 points or +0.58% while the Nasdaq closed UP +156.34 points or +0.81%
  • Monday: The Dow closed UP +35.41points or +0.08%, the S&P closed UP +24.25 points or +0.41% while the Nasdaq closed UP +128.85 points or +0.67%

Economic Data Docket:  Initial jobless claims (May), U.S. trade deficit (April), U.S. productivity (Q1), Fed Reserve Governor Adriana Kugler and Philadelphia Fed President Patrick Harker speeches                                                             

 

Q2 – June – 3 positive closes

  • May – 1 market holiday, 10 negative and 11 positive closes
  • Q2 - April – 10 negative and 11 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty

Sell Into Strength:

  • Beam Therapeutics (BEAM) closed up +$0.06 after Tuesday’s +$0.69 after Monday’s+$0.36 after Friday’s -$0.49 with a positive +$0.08 or +0.47% pre-open
  • CRISPR Therapeutics (CRSP) closed up +).01 after Tuesday’s+$1.09 after Monday’s +0.66 after Friday’s -$0.49 with a positive +$0.15 or +0.39% pre-open
  • Agenus (AGEN) closed up +$0.63 after Tuesday’s +$0.30 after Monday’s +$0.70 after Friday’s +$0.23 with a positive +0.18 or +3.20% pre-open on news
  • Verve Therapeutics (VERV) closed up +$0.44 after Tuesday’s+$0.045 after Monday’s +0.345 after Friday’s -$0.15 with a positive +0.01 or +0.19%

 

The BOTTOM LINE: Not a clairvoyant, there are session that are just a flip-of-the-coin

  • Is the cell and gene therapy sector, a bit over-extended?
  • Could sector share pricing currently be 5–10% too high and what weaker growth could mean for Fed’s rate cuts.

June ’25:

  • 6/4 – Wednesday closed positive with 18 positive, 13 negative and 4 flats
  • 6/3 - Tuesday closed positive with 24 positive, 8 negative and 3 flats
  • 6/2 - Monday closed positive with 25 positive, 7 negative and 3 flats

May ’25 last week: understand the “flow” of bad market and economic karma…

  • 5/30 – Friday closed negative with 6 positive, 26 negative and 3 flats
  • 5/29 –Thursday closed positive with 24 positive, 10 negative and 1 flat
  • 5/28 -Wednesday closed negative with 7 positive, 26 negative and 2 flats
  • 5/27 - Tuesday closed positive with 21 positive, 11 negative and 3 flats
  • 5/26 - Monday. Market closed - holiday

 

VIP … ECON DATA, investors will receive the latest U.S. jobs-market update from the Labor Department.

 

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • Still a believer after I wrote, about June… “Get back-in and re-test the sector waters after May’s cell and gene therapy sector ‘s month alternations, nibble!  Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

As always, brace ourself for more volatility, economics and their down trending affect?

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.